You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a ZIKA viral pseudoinfectious virus as ZIKA vaccine candidate (STTR Phase II)

    SBC: Tengen Biomedical Co            Topic: NIAID

    Development of Zika viral pseudoinfectious virus as zika vaccine candidate(Phase 2) Abstract Zika virus epidemics and the association of ZIKV infection with Guillain–Barré syndrome, and congenital disabilities, including microcephaly, led the World Health Organization to declare ZIKV a “Public Health Emergency of International Concern” in 2016. Since then, various ZIKV vaccine platforms hav ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  2. An augmented reality platform to reduce post-operative and chronic opioid use in pediatric cancer

    SBC: ALTALITY, INC.            Topic: NIDA

    PROJECT SUMMARY/ABSTRACT Pediatric opioid use is a public health crisis. In children, prescription opioids are the primary source of non- medical abuse as well as opioid-associated hospitalizations and deaths. Early opioid use in childhood is a known “gateway” to adulthood dependence and substance abuse disorders. Despite years of research, opioids remain the most commonly prescribed pain medi ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  3. Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD

    SBC: Aromha Inc            Topic: NIA

    Project Summary / Abstract Over 5.8 million Americans are currently affected by Alzheimerandapos;s disease (AD) with an economic burden estimated at andgt; $270 billion/year in 2020 that is projected to increase at least four fold over the next several decades. Accurate biomarkers have been developed that demonstrate that AD pathology is present 15 years of more prior to the onset of memory sympto ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  4. Improving adherence to evidence-based practice using an innovative and easy-to-use health IT solution

    SBC: ADHERE.LY, LLC            Topic: 104

    PROJECT SUMMARY/ABSTRACT Homework, or between-session practice of skills learned during therapy, is one of the most integral, yet underutilized components of high-quality, evidence-based mental health treatments (EBTs) such as Cognitive Behavioral Therapy (CBT). Many providers struggle to consistently develop, assign, and assess homework exercises with their patients, and many patients have diffic ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  5. Developing a RPN13 inhibitor for the treatment of Quadruple Negative Breast Cancer

    SBC: Up Therapeutics LLC            Topic: 102

    Quadruple negative breast cancer (QNBC), lacking the expression of ER (estrogen receptor), PR (progesterone receptor), HER2 (human epidermal growth factor receptor 2) and AR (androgen receptor), is the breast cancer subtype with the worst prognosis, and QNBC disproportionately afflicts African Americans. It has no standard-of-care treatment targets and thus efficacious and safe treatments must be ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  6. Family Supportive Supervisor Training and Workplace Assessment Tool

    SBC: WORK LIFE HELP, INC.            Topic: NIA

    Project Summary/Abstract The aging workforce with rising personal health, family, and eldercare demands are the defining work-life and public health issues of the 21st century. The number of Americans over age 65 will double over the next 25 years, and half of working adults are eldercare and sandwich (elders and children) caregivers. Most U.S. employees rely on their employers, especially their s ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  7. Development of Novel Therapeutic Molecules for Treatment of Squamous Head and Neck Cancers

    SBC: Mekanistic Therapeutics, LLC            Topic: 102

    Mekanistic Therapeutics seeks to design, discover, and develop anti-cancer agents that selectively inhibit multiple oncogenic pathways. Among Mekanistic’s portfolio are dual and highly selective inhibitors of EGFR and PI3 kinase, which were rationally designed to only target these two critical oncogenes. The PI3 kinase (PI3K)/AKT/mTOR pathway plays a central role in driving tumor cell survival a ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  8. Low Cost Electrochemical Gas Phase Nitric Oxide Generator for Biomedical Applications

    SBC: NOTA Laboratories, Inc.            Topic: NHLBI

    ABSTRACT: Therapeutic use of gas phase nitric oxide (NO) has several important applications in medicine. Since its first medical application more than 20 years ago, inhaled nitric oxide (INO) has become a mainstay of intensive care for lung failure patients. As a pulmonary vasodilator, INO is essential in neonatology, lung transplantation, and pulmonary hypertension. As an inhaled antiseptic agent ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  9. Portable hand-held proprietary xenon inhaler for rapid reduction of opioid withdrawal symptoms

    SBC: NOBILIS THERAPEUTICS, INC.            Topic: NIDA

    Summary/Abstract People with opioid use disorder (OUD) experience aversive opioid withdrawal symptoms (OWS) including nausea, diarrhea, vomiting, and anxiety, which emerge when blood opioid levels wane. These symptoms perpetuate unprescribed opioid use and accompanying morbidity and mortality, costing society nearly $80 billion per year. Withdrawal symptoms also emerge upon initiation of OUD pharm ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  10. I-Corps Project plan for:STTR Phase I Development of therapeutics to treat fentanyl overdose using a validated animal model

    SBC: TORRALVA MEDICAL THERAPUETICS LLC            Topic: NIDA

    Project Summary According to the Centers for Disease Control (CDC), synthetic opioids are currently the most common cause of overdose death in the U.S, while heroin and prescription opioid deaths have decreased significantly since 2017. Despite the widespread availability of naloxone, deaths from fentanyl and fentanyl analogues (F/FA) continue to rise in parallel with increasing reports of F/FA re ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government